Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Policy and Practice Reviews

Published on 17 Apr 2025

Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China

in Drugs Outcomes Research and Policies

Jie Weng
Nailiang Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1557876

223 views

Original Research

Accepted on 16 Apr 2025

Trajectories of Potentially Inappropriate Medication Use among Older Adults in Saudi Arabia

in Drugs Outcomes Research and Policies

Fouad F. Jabri
Yajun Liang
Kristina Johnell
Jette Möller

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1568160

Original Research

Accepted on 16 Apr 2025

Towards a Sustainable Rare Disease and Orphan Drug Ecosystem in Saudi Arabia: Policy Insights from a Multi-Stakeholder Workshop

in Drugs Outcomes Research and Policies

Ghada Mohammed Abozaid
Hussain Al-Omar
Abdulaziz Alrabiah
Asma Almuaither
Amy Jayne McKnight

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583477

183 views

Original Research

Accepted on 15 Apr 2025

A Multinational Cross-sectional Study on Knowledge, Attitudes, and Practices towards Magnesium Supplements

in Drugs Outcomes Research and Policies

Rana Abutaima
Muna Barakat
Samar Thiab
Hana M. Sawan
Malak Amer
Reem Alzayer
Doaa H Abdelaziz
Noha O. Mansour
Fatima Saleh
Wael Abu Dayyih

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1550695

Original Research

Published on 15 Apr 2025

Statins and long-term risk of revision surgery after total hip arthroplasty in osteoarthritis: a multi-source data linkage study

in Drugs Outcomes Research and Policies

Andrea D'Amuri
Barbara Bordini
Mauro Pagani
Jacopo Ciaffi
Claudio D'Agostino
Alberto Di Martino
Cesare Faldini
Francesco Ursini

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1492200

210 views

Original Research

Published on 14 Apr 2025

Off-label drug use in China after the Physician Law (2021): legal challenges and solutions

in Drugs Outcomes Research and Policies

Shenbao Liang
Fanxian Cai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1547418

373 views

Original Research

Published on 14 Apr 2025

Optimization and impact of an evidence-based pre-audit prescription decision system in primary healthcare settings

in Drugs Outcomes Research and Policies

Xiao-Hui Yue
Lei Yang
Jing-Jing Zhong
Hong-Mei Liu
Dan Wang
Xue Tao
Gao-Feng Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1491810

309 views

Systematic Review

Accepted on 11 Apr 2025

Comparative Effectiveness of Semaglutide versus Liraglutide, Dulaglutide or Tirzepatide: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Parisa Alsadat Dadkhah
Mohammad Amin Karimi
Farzad Sheikhzadeh
Mohammad Sadra Gholami Chahkand
Shayan Yaghoubi
Fatemeh Esmaeilpour Moallem
Mitra Sadat Deyhimi
Melika Arab Bafrani
Mehregan Shahrokhi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1438318

162 views

Brief Research Report

Accepted on 11 Apr 2025

Regulatory Challenges of Digital Health: The case of mental health applications and personal data in South Africa

in Drugs Outcomes Research and Policies

Marietjie Wilhelmina Maria Botes

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498600

113 views

Original Research

Published on 11 Apr 2025

From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)

in Drugs Outcomes Research and Policies

Sarah Sauchelli
Courtney Levy
Ari Gnanasakthy
Vaidehi Dave
Lynda Doward
Kristina A. Fitzgerald
Robyn Carson

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1536401

1,040 views

Clinical Trial

Published on 11 Apr 2025

Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study

in Drugs Outcomes Research and Policies

Guang Yang
Yaoyu Huang
Yifei Ge
Xiangbao Yu
Li Liu
Li Xiang
Bin Liu
Chaoqing Gao
Changhua Liu
Yong Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574679

265 views

Original Research

Accepted on 10 Apr 2025

Characteristics, Clinical Evidence and Implementation Effects of Conditional Approvals for Drugs in China, a Pooled Analysis from 2020 to 2023

in Drugs Outcomes Research and Policies

Li Yang
ShuoXin Fan
Jie Zhang
Geyun Huang
Yaoyang Tang
Lijia Xue

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1501525

Original Research

Published on 10 Apr 2025

Impact of clinical pharmacist interventions on medication administration via enteral feeding tubes in a neurology ward: a pre- and post-educational prospective study

in Drugs Outcomes Research and Policies

Yunus Emre Ayhan
Ömer Faruk Özkanlı
Şeyma Gözelizmir
Anmar Al-Taie
Mesut Sancar
Ipek Midi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1519835

347 views

Perspective

Published on 09 Apr 2025

Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action

in Drugs Outcomes Research and Policies

Tarek A. Hammad
Melissa Naylor
Dona M. Ely
Simon Davies

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1573353

662 views

Original Research

Accepted on 08 Apr 2025

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma

in Drugs Outcomes Research and Policies

Liangliang Zou
Cuihua Yuan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1500729

Original Research

Accepted on 08 Apr 2025

Effective inhaler technique education is achievable -assessment and comparison of five inhaler devices errors

in Drugs Outcomes Research and Policies

Monika Marko
Magdalena Klimczak
Marharyta Sobczak
Maciej Wojakiewicz
Tomasz Dębowski
Andrzej Emeryk
Rafał Pawliczak

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538283